Viral Inactivation Using Crosslinkers and Detergents
Description of Invention:
The subject technology is a method of inactivating enveloped viruses by hydrophobic photoactivatable chemical crossing-linking compounds and detergent treatment. The inactivated viruses may be used as vaccines against the diseases caused by those viruses or as reagents in experimental procedures that require inactivated viral particles. The compounds diffuse into the lipid bilayer of biological membranes and upon UV irradiation will bind to proteins and lipids in this domain, thereby inactivating fusion of enveloped viruses with their corresponding target cells. Furthermore, the selective binding of these chemical crosslinking agents to protein domains in the lipid bilayer may preserve the structural integrity and therefore immunogenicity of proteins on the exterior of the inactivated virus. The additional detergent step effectively eliminates the infectivity of any residual viral particles that are not adequately crosslinked.
Applications:
Vaccines for enveloped viruses
Vaccine for Human Immunodeficiency Virus
Advantages:
Novel method of inactivating enveloped viruses
May maintain native conformational structures and viral epitopes for generating an effective immune response
Development Status: In vitro data can be provided upon request
Market:
Vaccines
Inventors:
Julie M. Belanger et al. (NCI)
Patent Status:
DHHS Reference No. E-331-2007/0 --
U.S. Provisional Application No. 61/025,424 filed 01 Feb 2008
DHHS Reference No. E-331-2007/1 --
U.S. Provisional Application No. 61/088,294 filed 12 Aug 2008
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute, Center for Cancer Research, Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of hydrophobic crosslinkers for their use in vaccine development. Interested collaborators are also invited to provide statements for proposed in vitro or in vivo studies using various enveloped viruses. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Additional Information Please Contact: Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5018
Email: changke@mail.nih.gov
Fax: 301/402-0220
